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401 When should we discontinue antiarrhythmic therapy for atrial fibrillation
after coronary artery bypass grafting? A prospective randomized study
Uzi Izhar, MD, Niv Ad, MD, Ehud Rudis, MD, Eli Milgalter, MD, Amit Korach, MD,
Nicola Viola, MD, Eli Levi, MD, Galit Asraff, RN, BSN, Gideon Merin, MD, and
Amir Elami, MD, Jerusalem, Israel
One hundred twenty-nine patients in whom new AF developed after CABG and successfully
reverted to sinus rhythm were prospectively randomized at dismissal to receive antiarrhythmic
drugs for 1, 3, or 6 weeks. Antiarrhythmic therapy as short as 1 week may be appropriate in
these patients.
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407 Combined endothelial and myocardial protection by endothelin antagonism
enhances transplant allograft preservation
Paul W. M. Fedak, MD, PhD, Vivek Rao, MD, PhD, Subodh Verma, MD, PhD,
Danny Ramzy, MD, Laura Tumiati, BSc, Santiago Miriuka, MD, Patty Boylen,
Richard D. Weisel, MD, and Christopher M. Feindel, MD, Toronto, Ontario, Canada
Using a preclinical porcine model of orthotopic heart transplantation, we determined that ET-1
accumulates during allograft storage and contributes to early endothelial and myocardial
dysfunction after transplantation. ET-1 blockade during allograft preservation limited
endothelial injury and enhanced ventricular recovery after transplantation.
416 Rescue cardiac transplantation for early failure of the Fontan-type
circulation in children
Milind Chaudhari, MD, Jon Sturman, FRCA, John O’Sullivan, FRCP I, Jon Smith, FRCA, Neil
Wrightson, BSc, Gareth Parry, FRCP, David Bolton, FRCA, Simon Haynes, FRCA, Leslie
Hamilton, FRCS, and Asif Hasan, FRCS, Newcastle upon Tyne, United Kingdom
Six children underwent rescue cardiac transplantation for end-stage cardiac failure early after
the completion of the Fontan operation. One patient died intraoperatively. Five survivors are in
good condition with normal cardiac function. Challenges in the peritransplant intensive care
management and cardiac transplant surgery in this scenario are discussed.
423 A randomized, placebo-controlled trial of complement inhibition in
ischemia-reperfusion injury after lung transplantation in human beings
S. Keshavjee, MD, R. D. Davis, MD, M. R. Zamora, MD, M. de Perrot, MD, and
G. A. Patterson, MD, Toronto, Ontario, Canada; Durham, NC; Denver, Colo;
and St Louis, Mo
This randomized, double-blind, placebo-controlled trial demonstrated that a complement
inhibitor given before reperfusion can improve the postoperative course after lung
transplantation.
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